At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 88 enrolled
Drug / intervention
Dietary Supplement: Pregnenolone +1 moredrug
Likely dose
Dietary Supplement: Pregnenolone 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
In Brief
A Phase 2 clinical trial evaluating Dietary Supplement: Pregnenolone and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 88 participants across 1 site.
Detailed Summary
This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2008
Enrollment StartDec 2009
Primary CompletionMar 2015
Study CompletionDec 2015
TodayJul 2026
First PostedAug 6, 2008
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.9 years ago
Interventions
Dietary Supplement: Pregnenolonedrug
Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
Placebodietary
Placebo